Royalty Pharma plc Class A Ordinary Shares (RPRX) Stock Analysis
P/E 39.22×· 5Y range 12.63–102.43×· 62th percentile of history
Sector: Healthcare · Industry: Pharmaceutical Preparations
AnalystsStrong Buy16 analystsStrengths
- ✓Piotroski F-Score 7/9 — high earnings quality
What's happening with RPRX
Price History
5-Year Weekly Candlestick Chart
Profile
valuation and growth lag behind.
How is each axis scored?
- Valuation32/100 · Weak
- P/E vs own history (62th pct)5/25
- FCF yield (n/a)10/25
- P/S (10.6x)5/25
- EV/EBIT (21.4x)12/25
- Growth43/100 · Weak
- Revenue CAGR (1.0%)6/25
- Net income CAGR (5.6%)12/25
- EPS CAGR 5Y (-2.2%)0/25
- Fwd implied growth (277.5%)25/25
- Profitability67/100 · Moderate
- ROIC (7.0%)5/25
- ROE (8.3%)12/25
- Net margin (33.9%)25/25
- Operating margin (65.1%)25/25
- Financial Health66/100 · Moderate
- Altman Z (2.33)18/25
- Current ratio (2.66)25/25
- Interest coverage (7.0x)18/25
- Net cash / debt (D/A 40%)5/25
- Quality53/100 · Moderate
- Piotroski F (7/9)22/25
- Beneish M (-3.15)25/25
- FCF conversion (n/a)0/25
- Margin stability (σ 24.5%)6/25
About Royalty Pharma plc Class A Ordinary Shares
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. Show more
The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Headquarters: NEW YORK, NY · Employees: 100 · Website ↗
Insider Transactions
Recent SEC Form 4 filings
- SellOpen market sale · filed 2026-09-24-3927 sh2026-09-22
- SellOpen market sale · filed 2026-09-24-96073 sh2026-09-22
- SellGift · filed 2026-08-19-16800 sh2026-08-19
- SellOpen market sale · filed 2026-08-19-100000 sh2026-08-18
- SellOpen market sale · filed 2026-08-17-1772 sh2026-08-13
+3 more recent filings
Key Metrics
Financial snapshot — pillar inputs plus per-share and market context
Valuation
32DP/E (TTM)39.2xD
Grade D: ExpensivePrice / TTM EPS (own statements) — vs own 5Y history: 12.6x–102.4x · 62nd pct
P/FCF40.0xC
Grade C: ExpensivePrice / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield2.5%C
Grade C: LowTTM FCF / Market Cap
P/S (TTM)10.63xD
Grade D: ExpensivePrice / TTM Revenue (own statements) — vs own 5Y history: 6.4x–14.6x · 73rd pct
EV/EBIT21.4xC
Grade C: ExpensiveEnterprise value / TTM EBIT (D&A not in our data) — capital-structure neutral — vs own 5Y history: 12.3x–61.8x · 42nd pct
EV/Sales16.4xD
Grade D: Very expensiveEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E10.4xA
Grade A: CheapPrice / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio2.61xA
Grade A: FairPrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio3.89D
Grade D: ExpensiveFinnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield1.19%A
Grade A: PaysTTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio49.1%A
Grade A: SafeDividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
67BROIC7.0%D
Grade D: LowNOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE8.3%D
Grade D: WeakReturn on Equity. Neg. equity = heavy buybacks
ROA4.2%D
Grade D: WeakReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin33.9%A
Grade A: HighNet Income / Revenue
Operating Margin65.1%A
Grade A: HighTTM EBIT / TTM Revenue
Gross Margin65.1%A
Grade A: PremiumGross Profit / Revenue
FCF Margin—
FCF / Revenue
True FCF Margin—
TTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Financial Health
66BAltman Z-Score2.33C
Grade C: Gray zoneBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio2.66xA
Grade A: HighCurrent Assets/Liabilities
Quick Ratio2.40xA
Grade A: High(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage7.0xC
Grade C: OkEBIT/Interest. >10 Strong
Debt Repayment—
Years to repay net debt via FCF
Net Debt/EBIT5.0xD
Grade D: HighLeverage. <2x Low, >4x High
Debt/Equity0.86xA
Grade A: LowDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt0.07xD
Grade D: ThinCash covers how much of total debt. >1 = could repay all debt from cash
Growth
43D+Revenue CAGR1.0%D
Grade D: LowCompound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR5.6%C
Grade C: OkCompound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)-2.2%D
Grade D: LowCompound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth277.5%A
Grade A: HighImplied 1Y EPS growth from forward P/E vs our TTM EPS. Sparse — only where forward estimates exist
Dilution (5Y)-8.3%A
Grade A: BuybacksShare count change over 5Y
SBC / Net Income—
Stock-based comp/Net income. >30% = dilution risk
SBC / Revenue—
TTM stock-based comp / TTM Revenue
Quality
53CPiotroski F-Score7/9A
Grade A: StrongFinancial strength 0–9. >7 Strong
Beneish M-Score-3.15A
Grade A: SafeEarnings manipulation risk. < -2.22 Safe
FCF Conversion—
FCF / Net Income
Margin Stability24.5%D
Grade D: VolatileEBIT margin std deviation. Lower = stable
Capex / Revenue—
TTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.12xD
Grade D: LowRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
More metrics — Per Share, Balance Sheet, MarketHide additional metrics
Per Share
EPS (TTM)$1.49
Own TTM net income / shares — same earnings basis as P/E
Cash / Share$1.10
Cash & short-term investments per share (Finnhub)
Book Value / Share$11.22
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt$8.58B
Total debt obligations (short + long term)
Cash & Equiv.$608.29M
Cash and short-term investments
Net Debt$7.97B
Total Debt minus Cash. Negative = Net Cash position
Total Equity$9.94B
Shareholders' equity (book value)
Asset / Liability2.01xA
Grade A: SolidTotal Assets / Total Liabilities
Market
Market Cap$25.95B
Current Market Capitalization
Beta0.39B
Grade B: DefensivePrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
Takeaway
Current P/E of 39.2x sits at the 62nd percentile of its historical range.
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Mar 2026 · Ratio snapshot Sep 26, 2026
Key Insights: Royalty Pharma plc Class A Ordinary Shares (RPRX)
Royalty Pharma plc Class A Ordinary Shares meets 7 of 9 Piotroski F-Score criteria, placing its fundamental strength in the top tier of US-listed stocks. Altman Z-Score of 2.33 falls in the grey zone (1.81–2.99) — financial distress is unlikely but not ruled out.
- Beneish M-Score of -3.15 suggests a low likelihood of earnings manipulation.
See how RPRX ranks on the Capex Tracker — top 50 capital spenders compared.
No significant market moves for RPRX in the last 30 days.
See RPRX move history →Frequently Asked Questions about RPRX
Is RPRX stock a buy right now?
PreMarketPrice's quantitative model rates Royalty Pharma plc Class A Ordinary Shares's financial health at 66/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is RPRX stock overvalued?
Royalty Pharma plc Class A Ordinary Shares trades at a trailing P/E of 39.2 and our valuation score rates it 32/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does Royalty Pharma plc Class A Ordinary Shares report earnings?
No confirmed earnings date is currently scheduled for RPRX. The Earnings section lists recent reports and updates as dates are announced.
What sector does Royalty Pharma plc Class A Ordinary Shares operate in?
Royalty Pharma plc Class A Ordinary Shares operates in the Healthcare sector, within the Pharmaceutical Preparations industry. The Related Stocks section lists sector peers for comparison.
What does Royalty Pharma plc Class A Ordinary Shares do?
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties.
About Royalty Pharma plc Class A Ordinary Shares (RPRX) Stock
Royalty Pharma plc Class A Ordinary Shares (RPRX) is a US-listed stock operating in the Healthcare sector, specifically the Pharmaceutical Preparations industry. Real-time pricing data for Royalty Pharma plc Class A Ordinary Shares is available on this page with a market capitalization of $25.9 billion. The financial health score for RPRX is 66/100, which indicates good financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for RPRX stock.
RPRX Stock Analysis & Key Metrics
On PreMarketPrice, you can track Royalty Pharma plc Class A Ordinary Shares (RPRX) across multiple dimensions:
- Pre-market price & movement: Real-time RPRX stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for RPRX with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for Royalty Pharma plc Class A Ordinary Shares across multiple reporting periods.
- Financial health score: A composite score of 66/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for RPRX.
- Sector peers: Compare RPRX against 10 other healthcare stocks on key financial metrics.
Is RPRX a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate Royalty Pharma plc Class A Ordinary Shares (RPRX) as an investment. The financial health score of 66/100 suggests good financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.Royalty Pharma plc Class A Ordinary Shares (RPRX) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.